EP1421203A4 - Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules - Google Patents

Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules

Info

Publication number
EP1421203A4
EP1421203A4 EP02747843A EP02747843A EP1421203A4 EP 1421203 A4 EP1421203 A4 EP 1421203A4 EP 02747843 A EP02747843 A EP 02747843A EP 02747843 A EP02747843 A EP 02747843A EP 1421203 A4 EP1421203 A4 EP 1421203A4
Authority
EP
European Patent Office
Prior art keywords
prophylactic
enzymatic
diagnostic
screening
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02747843A
Other languages
German (de)
English (en)
Other versions
EP1421203A2 (fr
Inventor
Jay M Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diversa Corp filed Critical Diversa Corp
Publication of EP1421203A2 publication Critical patent/EP1421203A2/fr
Publication of EP1421203A4 publication Critical patent/EP1421203A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02747843A 2001-05-17 2002-05-17 Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules Withdrawn EP1421203A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30038101P 2001-05-17 2001-05-17
US300381P 2001-05-17
US30090701P 2001-06-25 2001-06-25
US300907P 2001-06-25
PCT/US2002/015767 WO2002092780A2 (fr) 2001-05-17 2002-05-17 Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules

Publications (2)

Publication Number Publication Date
EP1421203A2 EP1421203A2 (fr) 2004-05-26
EP1421203A4 true EP1421203A4 (fr) 2005-06-01

Family

ID=26971759

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02747843A Withdrawn EP1421203A4 (fr) 2001-05-17 2002-05-17 Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules

Country Status (3)

Country Link
EP (1) EP1421203A4 (fr)
JP (1) JP2004532038A (fr)
WO (1) WO2002092780A2 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4975324B2 (ja) * 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
EP2865687A1 (fr) 2003-12-10 2015-04-29 E. R. Squibb & Sons, L.L.C. Anticorps IP-10 et leurs utilisations
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
PL1781705T3 (pl) 2004-06-21 2015-03-31 Squibb & Sons Llc Antyciała receptora interferonów alfa I oraz ich zastosowania
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
PL1960434T3 (pl) 2005-12-08 2012-12-31 Squibb & Sons Llc Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US8586716B2 (en) 2006-08-04 2013-11-19 Novartis Ag EPHB3-specific antibody and uses thereof
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
US8450464B2 (en) 2006-10-02 2013-05-28 Medarex, Inc. Human monoclonal antibodies that bind CXCR4
ES2388567T3 (es) 2006-10-19 2012-10-16 Csl Limited Anticuerpos anti-il-13r alfa 1 y usos de los mismos
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
EA200900767A1 (ru) 2006-12-07 2009-12-30 Новартис Аг Антагонистические антитела против ephb3
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
JP5607530B2 (ja) 2007-09-04 2014-10-15 コンピュゲン エルティーディー． ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
PL2567709T3 (pl) 2007-11-02 2018-06-29 Novartis Ag Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
CA3102704A1 (fr) 2007-12-14 2009-06-25 Novo Nordisk A/S Anticorps humains anti-nkg2d et leurs utilisations
EP2641612A1 (fr) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Anticorps Alpha 5 - beta 1 et leurs utilisations
JP5504587B2 (ja) * 2008-05-27 2014-05-28 東レ株式会社 分析用チップ
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102300874B (zh) 2008-12-08 2015-08-05 卡姆普根有限公司 Tmem154多肽和多核苷酸及其作为产生药物和生物制品的药物靶标的用途
PT2403878T (pt) 2009-03-05 2017-09-01 Squibb & Sons Llc Anticorpos completamente humanos específicos a cadm1
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
US8715657B2 (en) 2009-04-27 2014-05-06 Novartis Ag Therapeutic antibodies binding IL12Rβ1
MY153078A (en) 2009-04-27 2014-12-31 Novartis Ag Compositions and methods for increasing muscle growth
SG10201505075TA (en) 2009-07-17 2015-07-30 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
WO2011021146A1 (fr) 2009-08-20 2011-02-24 Pfizer Inc. Anticorps contre l'ostéopontine
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (fr) 2009-09-25 2011-03-31 Xoma Technology Ltd. Procedes de criblage
EP2470569A1 (fr) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Anticorps anti-epha10
EP2507265B1 (fr) 2009-12-01 2016-05-11 Compugen Ltd. Anticorps spécifique pour la variante d'épissage héparanase T5 et son utilisation.
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
AU2011230537C1 (en) 2010-03-26 2018-08-02 Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
JP2013527762A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
US10106576B2 (en) * 2010-07-16 2018-10-23 Bioatla, Llc Methods of protein evolution
US8557248B2 (en) 2010-08-09 2013-10-15 Cyvax, Inc. Methods and compositions for treating malaria
MX2013002046A (es) 2010-08-20 2013-04-03 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA3182320A1 (fr) 2010-09-23 2012-03-29 Precision Biologics, Inc. Peptidomimetiques du cancer du colon et du pancreas
EP2625203A1 (fr) 2010-10-05 2013-08-14 Novartis AG Anticorps anti-il12rbêta1 et leur utilisation dans le traitement des troubles auto-immuns et inflammatoires
EP2658971A1 (fr) 2010-12-28 2013-11-06 XOMA Technology Ltd. Présentation sur surface cellulaire utilisant des domaines pdz
CA2830923A1 (fr) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides et polynucleotides et leurs utilisations pour un traitement de troubles lies au systeme immunitaire et du cancer
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
WO2012172495A1 (fr) 2011-06-14 2012-12-20 Novartis Ag Compositions et procédés de ciblage du tem8 par des anticorps
JP6247209B2 (ja) 2011-06-28 2017-12-13 オックスフォード ビオトヘラペウトイクス エルティーディー． Ａｄｐリボシルシクラーゼ２に対する抗体
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
CA2857601A1 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le recepteur 3 du facteur de croissance epidermique (her3) dirige contre le domaine ii de her3
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
WO2013114367A2 (fr) 2012-02-01 2013-08-08 Compugen Ltd. Anticorps de c10rf32 et leurs utilisations pour traiter le cancer
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN105246507B (zh) 2012-09-07 2019-01-25 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
KR102233664B1 (ko) 2012-12-05 2021-04-02 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
EP2938633B1 (fr) 2012-12-28 2018-02-07 Precision Biologics, Inc. Anticorps monoclonaux humanisés et méthodes d'utilisation pour le diagnostic et le traitement du cancer du côlon et du cancer du pancréas
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
JP2016514130A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
EP3033358A2 (fr) 2013-08-14 2016-06-22 Novartis AG Traitement de la myosite corps d'inclusion sporadique
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CN106459203B (zh) 2014-06-06 2021-08-03 百时美施贵宝公司 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
EP3161001A2 (fr) 2014-06-25 2017-05-03 Novartis AG Anticorps spécifiques pour il-17a fusé à des étiquettes de peptide de liaison hyaluronan
WO2015198243A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés pour protéines à action longue
WO2015198240A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés permettant d'obtenir des protéines à action prolongée
PT3177642T (pt) 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
WO2016020882A2 (fr) 2014-08-07 2016-02-11 Novartis Ag Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
SG11201703192SA (en) 2014-11-21 2017-05-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
TN2017000417A1 (en) 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CA2990360C (fr) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anticorps et fragments anti-vista
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
TN2018000076A1 (en) 2015-09-09 2019-07-08 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
MX2018003038A (es) 2015-09-09 2018-04-11 Novartis Ag Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
WO2017103895A1 (fr) 2015-12-18 2017-06-22 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation associés
WO2017137830A1 (fr) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anticorps anti-vista (b7h5)
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2017181139A2 (fr) 2016-04-15 2017-10-19 Michael Molloy Anticorps anti-vista humain et utilisation associée
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3471759A1 (fr) 2016-06-15 2019-04-24 Novartis AG Méthodes de traitement de maladie à l'aide d'inhibiteurs de la protéine morphogénétique osseuse 6 (bmp6)
CA3030765A1 (fr) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Anticorps anti-tim3 et leurs utilisations
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
AU2017353939A1 (en) 2016-11-07 2019-06-06 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
JP2020515283A (ja) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
EP3580237A1 (fr) 2017-02-08 2019-12-18 Novartis AG Anticorps mimétiques du fgf21 et leurs utilisations
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
CN110785433A (zh) 2017-06-28 2020-02-11 诺华股份有限公司 预防和治疗尿失禁的方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
BR112020010016A2 (pt) 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
WO2019140229A1 (fr) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Anticorps dirigés contre tim3 et leurs utilisations
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CA3094112A1 (fr) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Proteines de fusion de l'interleukine-2/du recepteur alpha de l'interleukine-2 et procedes d'utilisation
JP7530638B2 (ja) 2018-05-10 2024-08-08 ニューラクル サイエンス カンパニー リミテッド 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
AR117343A1 (es) 2018-12-18 2021-07-28 Novartis Ag AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
EP3902827A1 (fr) 2018-12-26 2021-11-03 Imcheck Therapeutics SAS Protéines de liaison btn3a et leurs utilisations
MX2021008796A (es) 2019-01-22 2021-11-12 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos.
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026446A1 (fr) * 2020-07-27 2022-02-03 Wisconsin Alumni Research Foundation Procédés de realisation de bibliothèques de phages non biaisées
EP4314068A1 (fr) 2021-04-02 2024-02-07 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
WO2023217743A1 (fr) 2022-05-10 2023-11-16 Imcheck Therapeutics Anticorps anti-btn3a à utiliser dans des méthodes de traitement de troubles inflammatoires gastro-intestinaux

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (fr) * 1990-04-05 1991-10-17 Roberto Crea Mutagenese 'traversante'
WO1998027230A1 (fr) * 1996-12-18 1998-06-25 Maxygen, Inc. Procedes et compositions pour l'ingenierie des polypeptides
WO2000018906A2 (fr) * 1998-09-29 2000-04-06 Maxygen, Inc. Rearrangement de genes modifies par codon
WO2000053744A2 (fr) * 1999-03-09 2000-09-14 Diversa Corporation Selection finale d'une evolution dirigee

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (fr) * 1990-04-05 1991-10-17 Roberto Crea Mutagenese 'traversante'
WO1998027230A1 (fr) * 1996-12-18 1998-06-25 Maxygen, Inc. Procedes et compositions pour l'ingenierie des polypeptides
WO2000018906A2 (fr) * 1998-09-29 2000-04-06 Maxygen, Inc. Rearrangement de genes modifies par codon
WO2000053744A2 (fr) * 1999-03-09 2000-09-14 Diversa Corporation Selection finale d'une evolution dirigee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORWITZ B H ET AL: "SATURATION MUTAGENESIS USING MIXED OLIGONUCLEOTIDES AND M13 TEMPLATES CONTAINING URACIL", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 185, 1990, pages 599 - 611, XP000993477, ISSN: 0076-6879 *
SCHULTZ S ET AL: "Site-saturation studies of beta-lactamase: production and characterization of mutant beta-lactamases with all possible amino acid substitutions at residue 71", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 83, no. 6, March 1986 (1986-03-01), pages 1588 - 1592, XP002147196, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002092780A3 (fr) 2004-03-25
EP1421203A2 (fr) 2004-05-26
JP2004532038A (ja) 2004-10-21
WO2002092780A2 (fr) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1421203A4 (fr) Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules
HK1085489A1 (en) Chitosan-containing polyaccharide, process for producing the same and use thereof
IL172871A0 (en) Rg1 antibodies and uses thereof
AU2002951274A0 (en) Methods for the chemical and physical modification of nanotubes, methods for linking the nanotubes, methods for the directed positioning of nanotubes, and uses thereof
MXPA03007197A (es) Moleculas de enlace terapeuticas.
EP1583428A4 (fr) Traitement des proteines laitieres et applications correspondantes
AU2002258388A1 (en) Narc8 programmed cell-death-associated molecules and uses thereof
AU2002245332A1 (en) Anergy-regulated molecules
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2001275990A1 (en) 16816 and 16839, novel human phospholipase c molecules and uses therefor
AUPR535101A0 (en) Novel therapeutic molecules
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
AU2002334781A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002327945A1 (en) Human delta-n p73 molecules and uses thereof
AU2002309646A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
EP1582589A4 (fr) Complexe de proteines, processus de fabrication et d'utilisation dudit complexe
GB0414424D0 (en) Polymer and process for producing polyer
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
WO2003023002A9 (fr) Nouvelles proteines humaines, polynucleotides codant ces proteines et procedes d'utilisation associes
AU2002337248A1 (en) Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
AU2002303232A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002302191A1 (en) Socs-5 molecules, screening therefore and therapeutic uses thereof
AU2002234236A1 (en) Process and product
AU2002254163A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050415

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12N 15/66 B

Ipc: 7C 12N 15/10 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060912